Latest From HOPA

Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Teclistamab-cqyv

Gavyn Walsh, PD3 Oncology Pharmacy Intern and Erin Kelley, PharmD, BCOP at M Health Fairview Masonic Cancer Clinic write about teclistamab-cqyv

Late Breaking News

Adapting Investigational Drug Services During a Pandemic

Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Futibatinib

Mei Ka Fong, Pharm.D., BCOP Clinical Pharmacist Coordinator Levine Cancer Institute, Atrium Health writes about Futibatinib

Pharmacist talking to a customer
Advocacy

The Value of Oncology Pharmacists Op-Ed

With Drug Shortages and Errors on the Rise, Oncology Pharmacists are Vital to Navigate Treatment in the Era of a Pandemic

Pharmacist talking to a customer
Advocacy

The Role of the Pharmacist after Dobbs v. Jackson Women’s Health Organization Ruling

The Hematology/Oncology Pharmacy Association (HOPA) is committed to optimizing cancer care for all individuals. The recent U.S. Supreme Court decision, which overturned Roe v. Wade, imposes a significant barrier to the oncology community’s ability to ens

Journal Club

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, M.D., M.B.A. abou-alg@mskcc.org, George Lau, M.D., F.R.C.P., Masatoshi Kudo, M.D., Ph.D., Stephen L. Chan, M.D., Robin Kate Kelley, M.D., Junji Furuse, M.D., Ph.D., Wattana Sukeepaisarnjaroen, M.D., +24 for the HIMALAYA Investigator

HOPA News

National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey

Oncology drug shortages often result in disruptions in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. The purpose of this survey was to characterize the

Heidi D. Finnes, PharmD, BCOP, FHOPA became President of the Hematology/ Oncology Pharmacy Association (HOPA) on April 1, 2022 at the association’s annual conference in  Boston, Massachusetts.
HOPA Members

HOPA President Brings Expertise and Unique Perspective to Hematology/Oncology Pharmacy Practice

Heidi D. Finnes, PharmD, BCOP, FHOPA became President of the Hematology/ Oncology Pharmacy Association (HOPA) on April 1, 2022 at the association’s annual conference in Boston, Massachusetts.

Large B-Cell Lymphoma
Journal Club

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects.

Pharmacist talking to a customer
Tools and Resources

Leading Oncology Healthcare Providers Release Online IV Cancer Treatment Education Sheets

The IVE website provides healthcare workers the latest education material for intravenous cancer treatments, communicating vital information to help caregivers and those experiencing cancer.

Advocacy

HOPA Calls for Appointment of Pharmacy Professionals to Federal COVID-19 Health Equity Task Force

HOPA has joined with 13 other pharmacy organizations to call on the White House to ensure pharmacy professionals are represented in the administration’s newly appointed COVID-19 Health Equity Task Force.

Person recieiving vaccine
Advocacy

5 Guiding Principles of COVID-19 Vaccine Distribution and Administration

HOPA joins the scientific community and public with enthusiasm on the recent historic Emergency Use Authorization approvals for the Pfizer-BioNTech ​and Moderna COVID-19 vaccine​s